CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 135 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $829 | -95.1% | 55,629 | +898.0% | 0.00% | – |
| Q1 2022 | $17,000 | -65.3% | 5,574 | -50.2% | 0.00% | – |
| Q3 2021 | $49,000 | +2.1% | 11,198 | 0.0% | 0.00% | – |
| Q2 2021 | $48,000 | +152.6% | 11,198 | +163.3% | 0.00% | – |
| Q1 2021 | $19,000 | – | 4,253 | +25.2% | 0.00% | – |
| Q4 2020 | $0 | – | 3,398 | -52.7% | 0.00% | – |
| Q3 2020 | $0 | – | 7,178 | -76.1% | 0.00% | – |
| Q2 2020 | $0 | -100.0% | 30,042 | +339.9% | 0.00% | – |
| Q4 2019 | $13,000 | +160.0% | 6,829 | +493.3% | 0.00% | – |
| Q3 2019 | $5,000 | -98.6% | 1,151 | -97.8% | 0.00% | -100.0% |
| Q2 2019 | $369,000 | +442.6% | 51,645 | +903.0% | 0.00% | – |
| Q1 2019 | $68,000 | +58.1% | 5,149 | -6.3% | 0.00% | – |
| Q4 2018 | $43,000 | 0.0% | 5,497 | +40.8% | 0.00% | – |
| Q3 2018 | $43,000 | – | 3,904 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |